Vera Therapeutics Names New Chief Regulatory Officer Amid Leadership Transition — Vera Therapeutics, Inc.

Event summary

William Turner, current Chief Regulatory Officer of Vera Therapeutics, plans to retire and transition to a Strategic Advisor role in Q3 2026.
Nancy Boman, M.D., Ph.D., will succeed Turner as Chief Regulatory Officer, bringing over 25 years of regulatory affairs experience.
Boman previously served as Chief Regulatory Officer at Kyverna Therapeutics and held similar roles at Adicet Bio, Encoded Therapeutics, and Novartis Gene Therapies.
Turner's tenure included the accelerated approval of Vera Therapeutics’ first therapy, TRUTAKNA™ (atacicept-vymj), for IgA nephropathy (IgAN).
Boman will focus on pursuing new indications for TRUTAKNA and developing approval pathways for other molecules in Vera Therapeutics' pipeline.

The big picture

Vera Therapeutics' appointment of Nancy Boman as Chief Regulatory Officer comes at a critical juncture, following the accelerated approval of TRUTAKNA for IgA nephropathy. The transition underscores the company's focus on expanding its regulatory footprint and advancing its pipeline in autoimmune kidney diseases. Boman's extensive experience in regulatory affairs and clinical development positions Vera Therapeutics to navigate complex approval pathways and potentially accelerate the development of new therapies.

What we're watching

Regulatory Strategy: How Nancy Boman's experience will shape Vera Therapeutics' approach to securing approvals for TRUTAKNA in new indications and other pipeline molecules.
Pipeline Development: The pace at which Vera Therapeutics can advance its pipeline under Boman's leadership, particularly in autoimmune kidney diseases.
Leadership Transition: Whether William Turner's transition to a Strategic Advisor role will ensure continuity in regulatory strategy during the leadership change.